MODIIN, Israel and NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, announced ...

After a rocky 2022 for VBL Therapeutics, the biotech is merging with Notable Labs, a cancer-focused platform company that just pulled in $10.3 million from investors. The merger, which is set to ...

When VBL Therapeutics’ viral cancer prospect flunked a phase 3 trial and sent investors sprinting last summer, the company was quick to take the budget ax to its pipeline, workforce and more.

Shares in VBL Therapeutics have lost around 78% of their value in pre-market trading after the company reported a phase 3 trial of its lead gene therapy VB-111 for ovarian cancer failed a pivotal ...

Israel-based VBL took ofra-vec, also known as VB-111, into phase 3 in the belief the adenovirus 5 therapy can improve outcomes in ovarian cancer by disrupting blood vessel growth and inducing an ...

MODIIN, Israel and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that it has closed on the previously announced sale of its manufacturing facility in ...